Results 161 to 170 of about 213,305 (310)
Bo Ding,1 Run Zhao,2 Xinyi Yue,2 Dexun Li2 1Pharmacy Department, Hefei Maternal and Child Health Hospital, Hefei, People’s Republic of China; 2School of Pharmaceutical Economics and Management, Anhui University of Chinese Medicine, Hefei, People’s ...
Ding B, Zhao R, Yue X, Li D
doaj
TRIPS, pharmaceutical patents, and generic competition in India. [PDF]
Kyle MK, Sampat BN, Shadlen KC.
europepmc +1 more source
ABSTRACT Some patients prescribed opioid pills fail to properly dispose of their unused pills, posing a risk for others. We report results from a pre‐registered field experiment testing whether behaviorally informed reminder cards increase participation in a financial incentive program for returning unused opioid pills among U.S. Veterans.
Mattie Toma +7 more
wiley +1 more source
Education as an upstream social security intervention: constructing a competency-based talent development framework in health economics. [PDF]
Luo H, Li A, Hua H.
europepmc +1 more source
ABSTRACT Syphilis, a sexually transmitted infection that can lead to serious health complications, was almost eliminated in the United States by 2000. But since then, its incidence began to increase, recently reaching a 60‐year peak. We suggest that the introduction of the highly active antiretroviral therapy (HAART) drug regimen, which transformed HIV
David Beheshti +2 more
wiley +1 more source
Pharmacy Benefit Manager Market Concentration for Prescriptions Filled at Retail Pharmacies by State and Payer Type. [PDF]
Qato DM, Chen Y, Van Nuys K.
europepmc +1 more source
Essays in Pharmaceutical Economics
This doctoral dissertation incorporates formal industrial organization and mechanism design analysis in the pharmaceutical industry in order to expand our understanding of modern pharmaceutical markets and provide new insights to key policy questions. The focus is primarily on the supply side of the pharmaceutical sector and in particular on questions ...
openaire +1 more source
Pharmaceutical Pricing and R&D as a Global Public Good
ABSTRACT This paper examines the international variation in the prices of branded pharmaceuticals. We consider short‐run profits, or quasi‐rents, as representing each country's contribution toward the global public good of therapeutic information embodied in new pharmaceuticals.
H. E. Frech III +3 more
wiley +1 more source
Pharmaceutical Economics in the Postwar Curriculum
openaire +2 more sources

